NewsBur
No Result
View All Result
Sunday, January 24, 2021
  • Home
  • Morning News
  • Market News
  • Analyst Actions
  • Trending Stocks
Subscribe
Newsbur
  • Home
  • Morning News
  • Market News
  • Analyst Actions
  • Trending Stocks
No Result
View All Result
Newsbur
No Result
View All Result
Home Analyst Actions

Johnson & Johnson [JNJ] is One of the Best Plays in Healthcare and This Proves It

by Shawn Johnson
October 8, 2020
in Analyst Actions
0
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Johnson & Johnson [NYSE:JNJ] is flashing a current price of $149.15. On Wednesday, the company’s daily low is at $145.81 as the high is reaching $148.23.

The price per sales of 4.87 and price per cash flow of 53.88. The company is also booking 5.58 earnings per share.

JNJ’s next earning date is 10/13/2020. The company has price per sales of 4.87 and price per cash flow of 53.88. The company is also booking 5.58 earnings per share.

Wait and see

Holding a Market Cap of $392.22 billion, Johnson & Johnson has seen a trading range over the last year of $109.16-$157.00.

For the last five days, JNJ is down from its last closing price. The average shares trading hands each day is 6.02M, with average 10-day volume coming in at 6.09 million.

Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for JNJ. When we apply the Elder Force Index to Johnson & Johnson, we are seeing an Elder Force Indicator number of 1459456.06.

Recent Performance

The recent performance of the stock is another area that can tell traders how to proceed. JNJ is presenting an interesting case. This can be seen in the Forward P/E ratio, which currently stands at 16.36. Moreover, the company’s enterprise value has gone from $379.75B to $353.59B quarter-over-quarter. Obviously, the company is heading in the wrong direction, but there are still opportunities for growth in the sector.

In the last quarter, JNJ made a profit of 11.76 billion. Johnson & Johnson also saw quarter revenue growth year over year of 0.71%. In addition, the company has operating cash flow of $20.74 billion.

Technical Analysis

Looking at popular technical indicators, the company’s 5-day moving average is 147.61 compared to the 50-day moving average of 148.89. So, traders might want to tread carefully if they are going to bid.

The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. JNJ currently holds a 9-day RSI of 58.22%, while 100-day RSI stands at 51.63%.

Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. JNJ’s 9-day MACD is 0.25 and the company’s 100-day MACD stands at 0.95.

Inside Moves

Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.

The major holders for this stock are 0.08% by insiders and 70.25% by institutions. Regarding institutional holdings, Vanguard Group, Inc. (The) owns 8.80%, while the second top holder, Blackrock Inc., currently owns 7.36%.

Over the last six months, insiders have sold 16,115 with the most recent transaction from Wengel Kathryn E, EVP, Chief GSC Officer, with a sell at price 153.52 per share.

Conclusion

Overall, the recommended rating for JNJ is Strong Buy. Currently, the company has 15 analysts watching the stock, and the average quarterly earnings estimate is 1.96. Quarterly revenue estimates are averaging 20.06B with the high estimate reaching 20.53B and the low at 19.33B.

To review, the current 1-year target estimate is sitting at 165.06, while the current price 149.15. Based on this, we expect the stock to rise considering the aforementioned fundamentals.

Tags: JNJJNJ stockJohnson & JohnsonNYSE:JNJ

Recommended Stories

Has Capitol Federal Financial Inc. [CFFN] Completely Outpaced Other Companies in the Financial This Year?

October 2, 2020

Ares Capital Corporation [ARCC] Stumbles to $14.79

August 31, 2020

Impressive Profit Margins of 5.70% Raise Bull Flags for DiamondRock Hospitality Company [DRH]

September 28, 2020

Popular Stories

  • Sorrento Therapeutics Inc. [SRNE] is One of the Best Plays in Healthcare and This Proves It

    0 shares
    Share 0 Tweet 0
  • Heat Biologics Inc. [HTBX] is One of the Best Plays in Healthcare and This Proves It

    0 shares
    Share 0 Tweet 0
  • Heat Biologics Inc. [HTBX] Is Skyrocketing 13.15% on Pure Fundamentals

    0 shares
    Share 0 Tweet 0
  • BlackBerry Limited [BB] is a Top Ten Buy with Quarterly Revenues of 999.00M

    0 shares
    Share 0 Tweet 0
  • Impressive Profit Margins of -5.80% Raise Bull Flags for General Electric Company [GE]

    0 shares
    Share 0 Tweet 0

NewsBur.com

Newsbur.com is an Economic news website, which offers broad information about the Stock markets and Equities. The major emphasis of this platform is to present, the most practical recommendation for public and private capital sharing, both in the form of updates and detailed analysis.

Recent Posts

  • After-Hours Trading Alert: Amgen Inc. [AMGN] is Up 0.85% After the Bell
  • Has Dynatrace Inc. [DT] Completely Outpaced Other Companies in the Technology This Year?
  • Why Applied Materials Inc. [AMAT]’s 1.55% Drop is No Cause for Alarm

Categories

  • Analyst Actions
  • Market News
  • Morning News
  • Trending Stocks
  • Uncategorized

© 2020 Copyright © All Rights Reserved.

No Result
View All Result
  • Home
  • Market News
  • Morning News
  • Analyst Actions
  • Trending Stocks

© 2020 Copyright © All Rights Reserved.